These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 16570004)
1. Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years. Kumar MS; Heifets M; Moritz MJ; Saeed MI; Khan SM; Fyfe B; Sustento-Riodeca N; Daniel JN; Kumar A Transplantation; 2006 Mar; 81(6):832-9. PubMed ID: 16570004 [TBL] [Abstract][Full Text] [Related]
2. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960 [TBL] [Abstract][Full Text] [Related]
3. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol. Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598 [TBL] [Abstract][Full Text] [Related]
4. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. Anil Kumar MS; Heifets M; Fyfe B; Saaed MI; Moritz MJ; Parikh MH; Kumar A Transplantation; 2005 Sep; 80(6):807-14. PubMed ID: 16210969 [TBL] [Abstract][Full Text] [Related]
5. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients. Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352 [TBL] [Abstract][Full Text] [Related]
6. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study. Nematalla AH; Bakr MA; Gheith OA; Elagroudy AE; Elshahawy el-M; Aghoneim M Exp Clin Transplant; 2007 Dec; 5(2):673-9. PubMed ID: 18194120 [TBL] [Abstract][Full Text] [Related]
8. Comparative study of clinical outcome in kidney transplantation between early steroid withdrawal protocol using basiliximab, calcineurin inhibitor, and mycophenolate mofetil and triple regimen consisting of calcineurin inhibitor, mycophenolate mofetil, and steroid. Teraoka S; Sato S; Sekijima M; Iwado K; Urashima Y; Kudo S; Kai K; Koyama I; Tojinbara T; Nakajima I; Fuchinoue S Transplant Proc; 2005 Mar; 37(2):791-4. PubMed ID: 15848533 [TBL] [Abstract][Full Text] [Related]
9. Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil. Le Meur Y; Thierry A; Glowacki F; Rerolle JP; Garrigue V; Ouali N; Heng AE; Delahousse M; Albano L; Lang P; Couzi L; Jaureguy M; Lebranchu Y; Mousson C; Glotz D; Kessler M; Vrtovsnik F; Rouanet S; Tagieva N; Kamar N Transplantation; 2011 Dec; 92(11):1244-51. PubMed ID: 22067312 [TBL] [Abstract][Full Text] [Related]
10. Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab. Heilman RL; Reddy KS; Mazur MJ; Moss AA; Post DJ; Petrides S; Mulligan DC Transplant Proc; 2006 Jun; 38(5):1307-13. PubMed ID: 16797289 [TBL] [Abstract][Full Text] [Related]